CDKN2A and non-small cell lung carcinoma: Twenty-five patients with previously treated advanced stage NSCLC, with documented p16-null status by immunohistochemistry, and with documented tumor progression on CT imaging using RECISTv1.1 [23] were enrolled onto a phase 2 clinical trial from April 2012 to June 2013.